| Autor: |
Natalucci, Francesco, Bisseron, Sandra, Sokolova, Tatiana, Avramovska, Aleksandra, Maiter, Dominique, Durez, Patrick |
| Přispěvatelé: |
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de rhumatologie |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Annals of the rheumatic diseases, Vol. 82, no.Suppl 1, p. 401-402 (2023) |
| Popis: |
BACKGROUND: Methotrexate (MTX) is the anchor drug of Rheumatoid Arthritis (RA) treatment. It is a safe and handy drug, but it has several well-known side effects mainly not severe such as nausea, fatigue, alopecia, or an increase in transaminases. In the last years, sexual dysfunction has been reported as a rare adverse effect of MTX therapy. OBJECTIVES: To explore this, the aim of this study is to evaluate the impact of MTX on erectile function in male patients through the IIEF5 questionnaire and hormonal dosage. METHODS: Male patients affected by inflammatory arthritis (Rheumatoid Arthritis or Psoriatic Arthritis [PsA]) according to the 2010 EULAR/ACR diagnostic criteria for RA and the 2006 CASPAR criteria for PsA and treated with chronic MTX were enrolled. Age-matched patients affected by chronic arthritis not treated with MTX were enrolled as control. Each patient underwent blood collection for a complete serum sexual hormone evaluation. IIEF5 questionnaire which consists of 5 items with a maximum score of 25 was administered to the patients. […] |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
